Abstract:Recent studies showed that the likelihood of drug approval can be predicted with clinical data and structure information of drug using computational approaches. Predicting the likelihood of drug approval can be innovative and of high impact. However, models that leverage clinical data are applicable only in clinical stages, which is not very practical. Prioritizing drug candidates and early-stage decision-making in the de novo drug development process is crucial in pharmaceutical research to optimize resource allocation. For early-stage decision-making, we need a computational model that uses only chemical structures. This seemingly impossible task may utilize the predictive power with multi-modal features including clinical data. In this work, we introduce ChemAP (Chemical structure-based drug Approval Predictor), a novel deep learning scheme for drug approval prediction in the early-stage drug discovery phase. ChemAP aims to enhance the possibility of early-stage decision-making by enriching semantic knowledge to fill in the gap between multi-modal and single-modal chemical spaces through knowledge distillation techniques. This approach facilitates the effective construction of chemical space solely from chemical structure data, guided by multi-modal knowledge related to efficacy, such as clinical trials and patents of drugs. In this study, ChemAP achieved state-of-the-art performance, outperforming both traditional machine learning and deep learning models in drug approval prediction, with AUROC and AUPRC scores of 0.782 and 0.842 respectively on the drug approval benchmark dataset. Additionally, we demonstrated its generalizability by outperforming baseline models on a recent external dataset, which included drugs from the 2023 FDA-approved list and the 2024 clinical trial failure drug list, achieving AUROC and AUPRC scores of 0.694 and 0.851. These results demonstrate that ChemAP is an effective method in predicting drug approval only with chemical structure information of drug so that decision-making can be done at the early stages of drug development process. To the best of our knowledge, our work is the first of its kind to show that prediction of drug approval is possible only with structure information of drug by defining the chemical space of approved and unapproved drugs using deep learning technology.

MultiCon: A Semi-Supervised Approach for Predicting Drug Function from Chemical Structure Analysis

Multimodal Protein-Ligand Contrastive Pretraining for Effective and Efficient Drug Discovery

Synergistic Multi-Drug Combination Prediction Based on Heterogeneous Network Representation Learning with Contrastive Learning

Self-supervised Learning for Drug Synergy Prediction with Small Data Set

Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning

Concept-Based Semi-Automatic Classification of Drugs

Synergizing Chemical Structures and Bioassay Descriptions for Enhanced Molecular Property Prediction in Drug Discovery

A multi-task learning model for predicting drugs combination synergy by analyzing drug-drug interactions and integrated multi-view graph data

Semi-supervised Contrastive Learning for Bioactivity Prediction using Cell Painting Image Data

Leveraging Multiple Types of Domain Knowledge for Safe and Effective Drug Recommendation.

Developing a Semi-Supervised Approach Using a PU-Learning-Based Data Augmentation Strategy for Multitarget Drug Discovery

Self-supervised Learning for Label Sparsity in Computational Drug Repositioning

A Novel Descriptor and Molecular Graph-Based Bimodal Contrastive Learning Framework for Drug Molecular Property Prediction.

Breaking the barriers of data scarcity in drug–target affinity prediction

Multimodal fused deep learning for drug property prediction: Integrating chemical language and molecular graph

MEDICASCY: A Machine Learning Approach for Predicting Small Molecule Drug Side Effects, Indications, Efficacy and Mode of Action.

ChemAP: predicting drug approval with chemical structures before clinical trial phase by leveraging multi-modal embedding space and knowledge distillation

Learning self-supervised molecular representations for drug–drug interaction prediction

An In Silico Method for Predicting Drug Synergy Based on Multitask Learning

Multi-modal chemical information reconstruction from images and texts for exploring the near-drug space

S-MolSearch: 3D Semi-supervised Contrastive Learning for Bioactive Molecule Search